TRAX
NASDAQ HealthcareFirst Tracks Biotherapeutics, Inc. - Ordinary Shares
Biotechnology
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
๐ Market Data
| Price | $43.60 |
|---|---|
| Volume | 480,395 |
| Market Cap | 1.56B |
| RSI (14-Day) | 53.6 |
| 50-Day MA | $30.29 |
| 52-Week High | $49.91 |
| 52-Week Low | $14.72 |
| Forward P/E | -12.97 |
| Price / Book | 9.14 |
๐ฏ Investment Strategy Scores
TRAX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (60/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Moon Shot (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TRAX in your text
Paste any article, transcript, or post โ the tool will extract TRAX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.